BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cells-Reference-Cited by-同舟云学术

BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cells

Published:2021-07 Issue:2 Volume:36 Page:109359
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Cano Carla E.,Pasero Christine,De Gassart Aude,Kerneur Clement,Gabriac Mélanie,Fullana Marie,Granarolo Emilie,Hoet René,Scotet Emmanuel,Rafia Chirine,Herrmann Thomas,Imbert Caroline,Gorvel Laurent,Vey Norbert,Briantais Antoine,le Floch Anne Charlotte,Olive Daniel

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference45 articles.

1. Human gamma delta T cells: Evolution and ligand recognition;Adams;Cell. Immunol.,2015

2. Structure of a human γδ T-cell antigen receptor;Allison;Nature,2001

3. Butyrophilin Btn2a2 inhibits TCR activation and phosphatidylinositol 3-kinase/Akt pathway signaling and induces Foxp3 expression in T lymphocytes;Ammann;J. Immunol.,2013

4. Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection;Ampuero;Genes Immun.,2015

5. Stimulation of Vγ9/Vδ2 T-lymphocyte proliferation by the isoprenoid precursor, (E)-1-hydroxy-2-methyl-but-2-enyl 4-diphosphate;Amslinger;Immunobiology,2007

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glycolysis inhibition affects proliferation and cytotoxicity of Vγ9Vδ2 T cells expanded for adoptive cell therapy;Cytotherapy;2024-09

2. Randomized Phase 2 Trial of Lirilumab as maintenance Treatment in Acute Myeloid Leukemia: Results of the EFFIKIR Trial;2024-08-23

3. Phosphoantigen recognition by Vγ9Vδ2 T cells;European Journal of Immunology;2024-08-15

4. Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemia;Blood Advances;2024-08-14

5. Overcoming limitations for antibody-based therapies targeting γδ T (Vg9Vd2) cells;Frontiers in Immunology;2024-07-31